Get started
Author

V. V. Antipova

Observed names: В. В. Антипова, Виктория Антипова
ORCID: 0000-0002-0006-3306
Observed ORCID: 0000-0002-0006-3306
OpenAlex ID: A5082827399
Effect of Differences in the Expression Levels Steroid Hormone Receptors and HER2 in the Primary Tumor and Metastatic Focus on the Efficacy of Eribulin Monotherapy in Metastatic Breast Cancer
2023 · Анастасия Стукань, Роман Мурашко, et al. · Voprosy Onkologii · 1
PDF
Predictive and prognostic features of early and locally advanced PIK3CA-mutated luminal HER2-negative breast cancer
2023 · A. I. Stukan, T. Yu. Semiglazova, et al. · Tumors of female reproductive system
PDF
Significance and possible causes of hormone receptor expression loss in metastatic breast cancer. Phenotypic evolution of luminal BRCA1-associated breast cancer to triple negative subtype in lung metastasis and PARP inhibition strategy in early-line therapy
2022 · A. I. Stukan, Z. K. Khachmamuk, et al. · Tumors of female reproductive system
PDF
Molecular features evaluation of metastatic foci as the basis for metastatic breast cancer treatment personalization. Is there a place of CDK4/6-inhibitors in late-line therapy after chemotherapeutic regimens?
2021 · A. I. Stukan, A. Y. Goryainova, et al. · Meditsinskiy sovet = Medical Council
PDF
Role of pre-metastatic niche in organ specificity of breast cancer metastasis. Influence on metastatic potential as a basis for CDK4/6-inhibition efficacy in early therapy of disseminated hormone-receptor-positive disease
2021 · A. I. Stukan, A. Yu. Goryainova, et al. · Meditsinskiy sovet = Medical Council
PDF
Works count: 6
Citation count: 1
H-index: 1
I10-index:
Year
Topic
Type